文献速递免疫规划

皮内分次剂量接种作为对mRNA COVID-19疫苗疑似过敏者的接种方法

Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
PubMed 文献 · Vaccine · 2024-06-29

研究对首剂肌内注射mRNA COVID-19疫苗后出现疑似过敏症状的成人,采用1/5分次皮内试验剂量接种mRNA-1273(Moderna)疫苗。皮内接种后(n=56)未观察到过敏反应,受试者(n=47)抗S1 IgG抗体浓度与既往全国队列标准肌内两剂接种相当。皮内分次剂量接种可能为疑似疫苗过敏者提供安全、省时、省剂量且具免疫原性的务实方案。

要点

  • 对mRNA COVID-19疫苗疑似过敏者,1/5分次皮内接种mRNA-1273未观察到过敏反应(n=56)。
  • 皮内接种后抗S1 IgG抗体浓度与标准肌内两剂接种的全国队列相当(n=47)。
  • 皮内分次剂量接种可能安全、省时、省剂量且具免疫原性。

核心结论

  • 皮内分次剂量接种mRNA COVID-19疫苗可能为疑似疫苗过敏者提供安全、省时、省剂量且具免疫原性的务实方案。

研究设计与样本

  • 对首剂肌内注射mRNA COVID-19疫苗后出现疑似过敏症状的成人,采用1/5分次皮内试验剂量接种mRNA-1273(Moderna)疫苗。
  • 皮内接种后(n=56)未观察到过敏反应。
  • 接种后四周使用基于珠的多重检测法测量血清抗S1 IgG浓度(n=47),并与既往全国队列(接受两剂肌内mRNA-1273)比较。

主要发现

  • 皮内接种后(n=56)未观察到过敏反应。
  • 所有受试者(n=47)的抗体反应与标准肌内接种相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Suspected allergic reactions after mRNA COVID-19 vaccination withheld multiple individuals from getting fully vaccinated during the pandemic. We vaccinated adults who had experienced possible allergic symptoms after their first intramuscular dose of a COVID-19 mRNA vaccine with a 1/5th fractional intradermal test dose of the mRNA-1273 (Moderna) COVID-19 vaccine. No anaphylactic reactions were observed after intradermal vaccination (n = 56). Serum anti-S1 IgG concentrations were measured using a bead-based multiplex assay four weeks after vaccinations. Antibody concentrations were compared with a previously collected nationwide cohort that had received two intramuscular doses of mRNA-1273. Antibody responses in all subjects tested (n = 47) were comparable to standard of care intramuscular dosing. Fractional intradermal dosing of mRNA COVID-19 vaccines may provide a pragmatic solution that is safe, time efficient compared to skin prick testing, dose sparing and immunogenic in individuals with suspected vaccine allergy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Roozen GVT, Granger A, van Binnendijk RS, et al. Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines. Vaccine. 2024. PMID: 38944578. doi:10.1016/j.vaccine.2024.06.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。